Inventiva S.A. (IVA:NASDAQ) closed at $3.71 on October 23, 2026, up 3.06% on the day. The stock trades 53.5% below its 52-week high of $7.98 and 31.6% above its 52-week low of $2.82. Over the past year, it lost 40.2%. Inventiva S.A. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, IVA closed higher on 119 days (47%). Its best day was July 7, 2026 (+16.92%) and its worst was October 28, 2025 (-23.62%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 2 times.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France.
Find more stocks like IVA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.